Company Filing History:
Years Active: 2015
Title: Innovations in Inflammatory Bowel Disease Treatment by Paul Hofman
Introduction
Paul Hofman, an accomplished inventor based in Nice, France, has significantly contributed to the field of biomedical research. With a focus on inflammatory bowel disease (IBD), his work aims to enhance treatment options and improve patient outcomes.
Latest Patents
Hofman holds a patent for an innovative method involving antagonists for the prevention or treatment of inflammatory bowel disease, particularly Crohn's disease. His invention targets the interaction between the Gp96 receptor and adherent-invasive Escherichia coli (AIEC) strains. The antagonist effectively blocks or reduces this interaction, focusing on the outer membrane vesicles (OMVs). The pharmaceutical compositions he developed may include an antibody against Gp96 or OmpA, or a polypeptide derived from either component. Additionally, the technology can be combined with antagonists that affect the interaction between the CEACAM6 receptor and AIEC strains, potentially utilizing an anti-CEACAM6 antibody or other related materials. Moreover, his invention provides methods for diagnosing inflammatory bowel disease and determining a person's predisposition to the condition.
Career Highlights
Paul Hofman is affiliated with Université d'Auvergne Clermont I, where he conducts advanced research in his field. His dedication to understanding and addressing the complexities of inflammatory bowel disease has positioned him as a notable figure in biomedical innovation.
Collaborations
Throughout his career, Hofman has collaborated with esteemed colleagues, including Arlette Darfeuille-Michaud and Nathalie Rolhion. These partnerships have enabled him to advance his research and foster the development of new therapeutic options for patients suffering from IBD.
Conclusion
Paul Hofman's work represents a significant advancement in the treatment of inflammatory bowel disease, showcasing the potential of targeted therapies in this challenging area of medicine. Through his innovative patent and collaborative efforts, he continues to contribute to the improvement of healthcare solutions for individuals affected by this condition.